Retos y avances hacia la medicina de precisión en el mieloma múltiple

Translated title of the contribution: Towards precision medicine in myeloma: New evidence and challenges

Verónica González-Calle, Rafael Fonseca

Research output: Contribution to journalArticle

Abstract

In the last few years, next-generation sequencing studies have provided insights into the mutational landscape of multiple myeloma. The identification of actionable mutations might give a precious opportunity for exploring new targeted therapies. Thus, the implementation of promising precision medicine strategies seems to be closer than ever. Throughout this review we describe the main challenges that should to be dealt with in this new era, in order to achieve the main goal of precision medicine, namely matching patients with their right drug. In addition, we provide a review of the most significant preclinical and clinical studies supporting the implementation of precision medicine nowadays. Finally, we highlight the need of clinical trials to evaluate the security and efficacy of these targeted therapies, as well as to validate predictive biomarkers that may allow an appropriate best-candidate selection and improvement of myeloma patients’ survival and quality of life.

Original languageSpanish
Pages (from-to)222-226
Number of pages5
JournalMedicina (Argentina)
Volume77
Issue number3
StatePublished - Jun 1 2017

Fingerprint

Precision Medicine
Multiple Myeloma
Biomarkers
Quality of Life
Clinical Trials
Mutation
Survival
Therapeutics
Pharmaceutical Preparations

Keywords

  • Driver mutation
  • Multiple myeloma
  • Personalized medicine
  • Targeted therapy

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Retos y avances hacia la medicina de precisión en el mieloma múltiple. / González-Calle, Verónica; Fonseca, Rafael.

In: Medicina (Argentina), Vol. 77, No. 3, 01.06.2017, p. 222-226.

Research output: Contribution to journalArticle

González-Calle, Verónica ; Fonseca, Rafael. / Retos y avances hacia la medicina de precisión en el mieloma múltiple. In: Medicina (Argentina). 2017 ; Vol. 77, No. 3. pp. 222-226.
@article{83ce0fdbb73d4c6486959759b43d8b50,
title = "Retos y avances hacia la medicina de precisi{\'o}n en el mieloma m{\'u}ltiple",
abstract = "In the last few years, next-generation sequencing studies have provided insights into the mutational landscape of multiple myeloma. The identification of actionable mutations might give a precious opportunity for exploring new targeted therapies. Thus, the implementation of promising precision medicine strategies seems to be closer than ever. Throughout this review we describe the main challenges that should to be dealt with in this new era, in order to achieve the main goal of precision medicine, namely matching patients with their right drug. In addition, we provide a review of the most significant preclinical and clinical studies supporting the implementation of precision medicine nowadays. Finally, we highlight the need of clinical trials to evaluate the security and efficacy of these targeted therapies, as well as to validate predictive biomarkers that may allow an appropriate best-candidate selection and improvement of myeloma patients’ survival and quality of life.",
keywords = "Driver mutation, Multiple myeloma, Personalized medicine, Targeted therapy",
author = "Ver{\'o}nica Gonz{\'a}lez-Calle and Rafael Fonseca",
year = "2017",
month = "6",
day = "1",
language = "Spanish",
volume = "77",
pages = "222--226",
journal = "Medicina (Argentina)",
issn = "0025-7680",
publisher = "Instituto de Investigaciones Medicas",
number = "3",

}

TY - JOUR

T1 - Retos y avances hacia la medicina de precisión en el mieloma múltiple

AU - González-Calle, Verónica

AU - Fonseca, Rafael

PY - 2017/6/1

Y1 - 2017/6/1

N2 - In the last few years, next-generation sequencing studies have provided insights into the mutational landscape of multiple myeloma. The identification of actionable mutations might give a precious opportunity for exploring new targeted therapies. Thus, the implementation of promising precision medicine strategies seems to be closer than ever. Throughout this review we describe the main challenges that should to be dealt with in this new era, in order to achieve the main goal of precision medicine, namely matching patients with their right drug. In addition, we provide a review of the most significant preclinical and clinical studies supporting the implementation of precision medicine nowadays. Finally, we highlight the need of clinical trials to evaluate the security and efficacy of these targeted therapies, as well as to validate predictive biomarkers that may allow an appropriate best-candidate selection and improvement of myeloma patients’ survival and quality of life.

AB - In the last few years, next-generation sequencing studies have provided insights into the mutational landscape of multiple myeloma. The identification of actionable mutations might give a precious opportunity for exploring new targeted therapies. Thus, the implementation of promising precision medicine strategies seems to be closer than ever. Throughout this review we describe the main challenges that should to be dealt with in this new era, in order to achieve the main goal of precision medicine, namely matching patients with their right drug. In addition, we provide a review of the most significant preclinical and clinical studies supporting the implementation of precision medicine nowadays. Finally, we highlight the need of clinical trials to evaluate the security and efficacy of these targeted therapies, as well as to validate predictive biomarkers that may allow an appropriate best-candidate selection and improvement of myeloma patients’ survival and quality of life.

KW - Driver mutation

KW - Multiple myeloma

KW - Personalized medicine

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85027552856&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027552856&partnerID=8YFLogxK

M3 - Article

VL - 77

SP - 222

EP - 226

JO - Medicina (Argentina)

JF - Medicina (Argentina)

SN - 0025-7680

IS - 3

ER -